Study to Investigate the Potential Pharmacological Effect of Oral Palmitoylethanolamide (PEA) Therapy in the Management of Low Back Pain (Neuropathic Pain)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-28

Study Completion Date

2025-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial aims to evaluate the potential therapeutic effects of oral supplemental Palmitoylethanolamide (PEA) Phytosome® in managing neuropathic low back pain. The study will involve adult participants diagnosed with neuropathic pain according to established criteria. Eligible participants will be randomized into three groups to receive either PEA Phytosome® supplementation as two different doses or a placebo for a specified period. Data collection will include demographic information, baseline pain intensity, quality of life assessments, and functional outcomes. The primary endpoint will be the reduction in pain intensity, while secondary endpoints will include improvements in quality of life and functional capacity. Safety and tolerability of the supplement will also be assessed. This trial seeks to provide robust clinical evidence of the potential pharmacological effect of PEA's Phytosome® as a potential adjunctive treatment for neuropathic low back pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

NCT06273462

Chronic Pain

RECRUITING PHASE2

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

NCT05246670

Chemotherapy-Induced Peripheral Neuropathy Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

ACTIVE_NOT_RECRUITING PHASE2

Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain

NCT01851499

Neuropathic Pain Spinal Cord Injury

COMPLETED NA

Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.

NCT06157177

Sciatica Acute Lumbar Spinal Stenosis

ACTIVE_NOT_RECRUITING PHASE4

Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain

NCT06247813

Chronic Pain

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neuropathic low back pain arises from nerve damage or dysfunction, leading to chronic pain characterized by burning, tingling, or shooting sensations. This condition significantly impacts quality of life and is often refractory to conventional treatments. Palmitoylethanolamide (PEA) is an endogenous lipid mediator known for its anti-inflammatory, analgesic, and neuroprotective properties. PEA exerts its effects by modulating the endocannabinoid system and reducing the activation of mast cells and glial cells, which play a crucial role in chronic pain mechanisms. Its potential as a therapeutic agent for neuropathic pain has been demonstrated in preclinical and clinical studies, making it a promising candidate for managing neuropathic low back pain.

In the present randomized, double-blind, placebo-controlled, parallel-group clinical trial, the investigators aim to evaluate the therapeutic effect of a novel bioavailable oral formulation of PEA's Phytosome® in the management of neuropathic low back pain in healthy adult population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

300 mg Palmitoylethanolamide (PEA) group

Participants will receive 2 × 300 mg oral PEA Phytosome® tablets daily for one week, and a single tablet from week-7 to week-8, as add-on to the standard of care.

Group Type EXPERIMENTAL

300 mg Palmitoylethanolamide (PEA) Phytosome®

Intervention Type DIETARY_SUPPLEMENT

Oral supplement intake

450 mg Palmitoylethanolamide (PEA) group

Participants will receive 1 × 450 mg oral PEA Phytosome® tablet, and 1 placebo tablet daily for 8-weeks as add-on to the standard of care.

Group Type EXPERIMENTAL

450 mg Palmitoylethanolamide (PEA) Phytosome®

Intervention Type DIETARY_SUPPLEMENT

Oral supplement intake

Control group

Intervention Type OTHER

Placebo

Control group

Participants will receive 2 × placebo tablets daily for 8-weeks as add-on to the standard of care.

Group Type PLACEBO_COMPARATOR

Control group

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

300 mg Palmitoylethanolamide (PEA) Phytosome®

Oral supplement intake

Intervention Type DIETARY_SUPPLEMENT

450 mg Palmitoylethanolamide (PEA) Phytosome®

Oral supplement intake

Intervention Type DIETARY_SUPPLEMENT

Control group

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults, both Male or female aged ≥ 18 years and ≤ 80 years;
* Diagnosed with neuropathic lower back pain for at least 3 months, as confirmed by clinical evaluation and DN4 (neuropathic pain 4 questions) screening questionnaire with score ≥4.
* Pain intensity score ≥ 5 measured by NRS (Numerical Rating Scale) score, over the past week.
* Willingness to adhere to study protocol, including visits, assessments, and self-reporting of symptoms.
* Ability to provide informed consent and comply with study requirements.

Exclusion Criteria

* Known intolerance or allergy to any component of the tested nutraceuticals
* Presence of acute systemic disease
* Presence of significant organic pathology
* Current or past history of alcohol or drug abuse
* History of malignancy within the past 5 years
* Any significant concomitant disease or clinical condition that could compromise participant safety or interfere with study completion
* Women of childbearing potential not using reliable contraceptive methods
* Pregnancy or breastfeeding
* Severe psychiatric disorders (e.g., major depression, schizophrenia) that could affect pain perception or adherence.
* Inability to adhere to the study requirements due to lifestyle, transportation, or cognitive impairment.
* Use of other cannabinoid-based therapies, investigational drugs, or concurrent participation in another clinical trial.
* Dependence on opioid analgesics or recent opioid use that may interfere with pain assessment.
* Current use of other supplements with potential anti-inflammatory or analgesic effects, including Omega-3 Fatty Acids, Turmeric/Curcumin, Glucosamine and Chondroitin, Boswellia Serrata, Methylsulfonylmethane.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes